VIVUS Inc. (VVUS)

4.12
0.17 4.30
NASDAQ : Health Technology
Prev Close 3.95
Open 4.00
Day Low/High 4.00 / 4.15
52 Wk Low/High 2.15 / 6.41
Volume 59.49K
Avg Volume 74.50K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 41.72M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

FDA Ends October With Drug Approvals, Rejection

FDA approves drugs from Forest Labs and Avanir but rejects Biodel in what was a tough month overall for drug reviews.

Vivus Lives to Fight Another Day

FDA rejects Vivus' weight-loss drug but the company hopes to answer regulators safety concerns in time for drug to be approved next year.

Vivus: What Defines A Weight-Loss Win?

What to expect Thursday when FDA issues an approval decision on Vivus' weight-loss drug Qnexa.

Arena's 'Path Forward' Shrouded in Fog

Arena's CEO insists his rejected weight-loss drug is approvable eventually, but he offers few details on how that happens.

Arena Obesity Drug Faces Uncertain Future

Arena Obesity Drug Faces Uncertain Future

Arena has a challenging road ahead to recover from FDA's rejection of its weight-loss drug lorcaserin.

Readers Pick Drug Approval Winners & Losers

FDA will approve drugs by Alkermes and Amylin but will turn away Arena and Vivus, according to reader predictions in TheStreet's FDA Drug-Approval Contest

Biotech Calendar: Key Dates for October

Here's a list of October's potentially stock-moving biotech events.

Biotech Stock Mailbag: Vivus

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Vivus: Weight Loss Extends Two Years

Vivus: Weight Loss Extends Two Years

Vivus' hopes positive, two-year weight-loss data persuades FDA to approve Qnexa.

Biotech Investor Calendar: Obesity Drugs

Biotech Investor Calendar: Obesity Drugs

Despite two FDA panel setbacks, investors eyeing obesity drugs still face a full calendar of events through the end of the year.

Weight Watchers Isn't Swallowing Biotech Cure

Weight Watchers Isn't Swallowing Biotech Cure

Ineffective pills and the costs of obesity will bring spending back to weight loss, an executive says.

Arena Pharma Plunges on FDA No Vote

Arena Pharmaceuticals shares fall 41% after hours after an FDA committee votes against its weight-loss drug lorcaserin.

Arena Pharma: FDA Panel Live Blog

Arena brings its weight-loss drug lorcaserin in front of an FDA advisory panel today.

Arena Drops After Initial FDA Review

Arena Drops After Initial FDA Review

Arena shares fell sharply Tuesday after medical reviewers said the company's experimental weight-loss drug lorcaserin was effective only by a slim margin.

Arena Tanks on Drug Safety Concerns

Arena Tanks on Drug Safety Concerns

Arena Pharmaceuticals shares are down more than 35% on three safety issues raised by the FDA.

Arena Pharma Will Fail: Hedge Fund Poll

Arena Pharma Will Fail: Hedge Fund Poll

Hedge funds surveyed predict a bad outcome for Arena's weight loss drug at an FDA panel next week, just one of many differing opinions of the drug.

21 Drugs Facing FDA Approval Decisions

21 Drugs Facing FDA Approval Decisions

Here is the updated list of drugs facing FDA approval decisions.

Biotech Stock Mailbag Readers' Portfolio: Update

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 23% this year.

Arena Pharma: Deja Vu Danger

Will an FDA advisory panel worried about being second-guessed over unsafe or ineffective drugs send Arena's weight-loss drug to the showers?

VIVUS Inc. Q2 2010 Earnings Call Transcript

VIVUS Inc. Q2 2010 Earnings Call Transcript

Biotech Stock Mailbag: Ziopharm

Biotech Stock Mailbag: Ziopharm

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Breakout Stocks: Altria, MasterCard, Halliburton

Breakout Stocks: Altria, MasterCard, Halliburton

Here 's a look at a number of stocks that could be setting up to become great breakout candidates.

Making an Exit

Closing out our holding in this pharmaceutical name, based on disappointing news regarding its promising obesity drug.

Joe's Jeans, Vivus: Volume Movers

Several stocks trading near $5, including Joe's Jeans, were poised to move on above-average volume Friday.

Vivus: What Happens Next?

Vivus' weight-loss drug can still be approved but a delay is most likely.

Review of Advisory Committee Outcome

While this pharmaceutical name did not receive the results it had hoped for, more studies are pending for its product.

Update on a Holding

Thus far, there have been no surprises during this pharmaceutical company's discussions with the FDA about one of its products.

Vivus' FDA Advisory Panel: Live Blog Recap

Vivus' FDA Advisory Panel: Live Blog Recap

Here's our live coverage of the FDA review of Vivus's weight-loss drug, Qnexa.

TheStreet Quant Rating: D (Sell)